^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM1080

    i
    Other names: PM1080, HS-20117
    Associations

    News

    Trials
    Company:
    Biotheus, Jiangsu Hansoh Pharma
    Drug class:
    EGFR inhibitor, c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=780, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    cisplatin • carboplatin • 5-fluorouracil • GSK5764227 • PM1080
    6ms
    HS-20117 301: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=1080, Not yet recruiting, Hansoh BioMedical R&D Company
    New P2/3 trial • Metastases
    |
    Ameile (aumolertinib) • PM1080
    over1year
    A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=322, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PM1080